文献速递肿瘤 PET/CT

晚期图像重建对低PSA生化复发前列腺癌18F-DCFPyL PET/CT病灶检出及观察者一致性的影响

Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer.
PubMed 文献 · J Nucl Med · 2019-09-03

共识分析中晚期重建未提高生化复发定位率(62.5%-66.7% vs 62.5%),但个体判读中2 mm重建阳性扫描更多、检出病灶数更多,观察者一致性未改善。

要点

  • 共识判读下晚期重建未提高低PSA生化复发的定位率
  • 个体判读中2 mm重建阳性率更高且检出病灶数更多
  • 晚期重建未改善观察者间一致性

核心结论

  • 在低PSA生化复发患者中,应用晚期图像重建未在读者共识层面提高18F-DCFPyL PET/CT的生化复发定位率。
  • 个体判读阳性扫描数增加提示图像重建方法进一步发展可能有助于改善生化复发定位。
  • 与标准4 mm重建相比,晚期重建未观察到观察者间一致性的改善。

研究设计与样本

  • 图像分别以4 mm和2 mm体素重建,各自联合或不联合点扩散函数。
  • 所有扫描由4名核医学医师判读,并以至少3名读者判读为阳性作为共识阳性。
  • 另纳入5例原发前列腺癌且淋巴结清扫后证实无淋巴结转移的患者,用于评估晚期重建引入假阳性病灶的风险。

主要发现

  • 共识分析中,晚期重建的生化复发定位率为62.5%-66.7%,4 mm重建为62.5%。
  • 个体判读中,2 mm重建阳性率为74.0%(95%CI 65.0%-82.9%,P=0.027),2 mm联合点扩散函数为75.0%(95%CI 66.2%-83.8%,P=0.014),均高于4 mm重建的65.6%(95%CI 56.0%-75.3%)。
  • 2 mm扫描检出病灶数中位2个(四分位距1-3),多于4 mm扫描的中位1个(四分位距0-3,P=0.008)。
  • 晚期重建的观察者间一致性为80.6%-84.7%,4 mm扫描为75.7%(P=0.08-0.25)。
  • 在5例原发前列腺癌患者中,不同重建方法观察到的假阳性病灶数量相等(总体n=13)。

临床怎么用

  • 对于低PSA生化复发患者,采用晚期重建可能增加个体判读的阳性检出和病灶数,但需注意共识层面定位率未提高。
  • 晚期重建未改善观察者间一致性,判读时仍需关注不同重建方法间的差异。
  • 在原发前列腺癌淋巴结清扫证实无转移的患者中,不同重建方法的假阳性病灶数量相等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biochemically recurrent prostate cancer (BCR) is the main indication to perform prostate-specific membrane antigen PET/CT. However, localizing BCR with prostate-specific membrane antigen PET/CT remains challenging in patients with low prostate-specific antigen (PSA) values. Here, we studied the impact of advanced PET image reconstruction methods on BCR localization and interobserver agreement with 18F-DCFPyL PET/CT scans in patients with BCR and low PSA values. Methods: Twenty-four patients with BCR and a PSA level of less than 2.0 ng/mL were included. PET images were reconstructed with 4-mm voxels and 2-mm voxels, both with and without point-spread function. All scans were interpreted by 4 nuclear medicine physicians. Additionally, PET examinations of 5 patients with primary prostate cancer and confirmed absence of lymph node metastases (after lymph node dissection) were included, to assess the risk of introducing false-positive findings when using advanced reconstruction. Calculation of BCR localization rates (scan positivity) was based on consensus among our readers (≥3 readers regarding a scan positive for BCR), as well as the individual scan interpretations of the readers. Results: In the consensus analysis, BCR localization rates were not higher using advanced reconstruction (62.5%-66.7%) than using 4-mm reconstruction (62.5%). On the basis of individual readings, however, more scans were positive using 2-mm reconstruction (74.0%; 95% confidence interval [CI], 65.0%-82.9%) (P = 0.027) and 2-mm reconstruction with point-spread function (75.0%; 95% CI, 66.2%-83.8%) (P = 0.014) than 4-mm reconstruction (65.6%; 95% CI, 56.0%-75.3%). A higher number of lesions was detected on the 2-mm scans (median, 2 lesions; interquartile range, 1-3) than the 4-mm scans (median, 1; interquartile range, 0-3; P = 0.008). The advanced reconstruction methods did not increase interobserver agreement (80.6%-84.7%), compared with the 4-mm scans (75.7%, P = 0.08-0.25). In the patients with primary prostate cancer, an equal number of false-positive lesions was observed among the different reconstruction methods (overall, n = 13). Conclusion: Applying advanced image reconstruction for 18F-DCFPyL PET/CT scans did not increase BCR localization in patients with BCR and low PSA values (reader consensus). Yet, the increased number of positive individual readings may imply that further development of image reconstruction methods holds potential to improve BCR localization. No improved interobserver agreement was observed with advanced reconstruction compared with standard 4-mm reconstruction.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jansen BHE, Jansen RW, Wondergem M, et al. Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2019. PMID: 31481580. doi:10.2967/jnumed.118.222513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。